Revised clinical guidance on the management of steroid induced hyperglycaemia and steroid induced diabetes has been published, with Trend Co-Chair June James a joint author.
Produced by the Joint British Diabetes Societies for Inpatient Care, the document, Management of Hyperglycaemia and Steroid (Glucocorticoid) Therapy, has been designed for use by general physicians and was revised in May 2021.
Along with a new section which examines the impact that COVID-19 has had on the use of steroids, the document also includes further evidence-based information to assist healthcare professionals working in hospital, and when reviewing people in hospital clinics and GP practices following a hospital admission.
The document is presented as ‘how to’ pages, covering the following areas:
- Mechanism of action
- Discharge planning
- Special populations
- Dexamethasone and COVID-19
- End of life care
June, who is also an Associate Professor at the University of Leicester, said: “This document aims to guide the management of hyperglycaemia in people given steroids as a hospital inpatient and following discharge.
“There is no generally accepted management strategy but there is now more clarity over the impact the use of steroids can have on people already known to have diabetes and those without a previous diagnosis of the condition. Steroid induced diabetes may be frequently undiagnosed and only discovered on the mergence of symptoms or complications of acute hyperglycaemia.”
The assessment of hyperglycaemia in individuals is presented in three separate arms:
- Management in people with steroid induced diabetes (no known diabetes diagnosis)
- Management of people with steroid induced hyperglycaemia in those with a pre-existing diabetes diagnosis
- End of life care
To read the guidance, click here.
This content is restricted to site members. If you are an existing user, please log in. New users may register below.